Multivariate Analysis Utilizing MMC Algorithm. All development of multivariate statistical models for distinguishing ovarian cancer cases from benign controls was restricted to the training set (modelers were blinded to all data in the validation set) until one panel and one model of combining the candidate biomarkers in the panel was selected. This approach avoided overfitting bias in estimating the operating characteristics when the best panel was evaluated on the validation set. The natural logarithm was applied to transform the span of concentrations to an arithmetic scale and to transform their distribution closer to a symmetric one. A Metropolis algorithm with Monte Carlo simulation (MMC) was utilized for analysis of the data [1, 2] . In MMC analysis the Scoring Function (SF) for a specific biomarker panel was constructed as a linear combination of logarithms of biomarker concentrations (with minimal detectable concentration added to each concentration to reduce the effect of large relative errors near zero concentrations). The Monte Carlo optimization was then used to determine the coefficients in this linear combination that for the training set provide the best SN(the minimal number of misdiagnosed cancer cases) at the desired SP (fixed number of misdiagnosed control cases). The cutoff was adjusted at each iteration of parameter estimates to maintain 85% SP. The advantage of using the number of misdiagnosed cancers as the optimization criterion is that it does not rely 6. Supplementary Material
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Materials and Methods
Multivariate Analysis Utilizing MMC Algorithm. All development of multivariate statistical models for distinguishing ovarian cancer cases from benign controls was restricted to the training set (modelers were blinded to all data in the validation set) until one panel and one model of combining the candidate biomarkers in the panel was selected. This approach avoided overfitting bias in estimating the operating characteristics when the best panel was evaluated on the validation set. The natural logarithm was applied to transform the span of concentrations to an arithmetic scale and to transform their distribution closer to a symmetric one. A Metropolis algorithm with Monte Carlo simulation (MMC) was utilized for analysis of the data [1, 2] . In MMC analysis the Scoring Function (SF) for a specific biomarker panel was constructed as a linear combination of logarithms of biomarker concentrations (with minimal detectable concentration added to each concentration to reduce the effect of large relative errors near zero concentrations). The Monte Carlo optimization was then used to determine the coefficients in this linear combination that for the training set provide the best SN(the minimal number of misdiagnosed cancer cases) at the desired SP (fixed number of misdiagnosed control cases). The cutoff was adjusted at each iteration of parameter estimates to maintain 85% SP. The advantage of using the number of misdiagnosed cancers as the optimization criterion is that it does not rely 6. Supplementary Material on any assumptions regarding the statistical distribution of the data and as a result the optimal linear combination is practically insensitive to the presence of outliers and erroneous data.
However, the choice of SF does restrict the combination of biomarkers to linear combinations in order to provide an optimum separation. Therefore, no cases were excluded from this analysis.
All possible panels consisting of 2, 3 and 4 biomarkers were evaluated for SN at 85% SP. For each panel size, the 500 panels with the best SN at 85% SP on the full data set we re-estimated the SN with cross-validation. For cross-validation, 20% of subjects were randomly excluded from the data set and the remainder used as a training set to build the optimal SF. The resultant model was applied to the excluded subjects, and this process was repeated 400 times which was sufficient to obtain a smooth averaged ROC curve. Twenty panels for each panel size demonstrating the best SN at 85% SP as determined from the ROC curves were retained for the next step. Optimal panels were chosen that offered high cross-validated SN for both early and late stage ovarian cancer and high specificity for benign pelvic disease. These panels and method of combination were evaluated on the validation set to estimate, free from selection bias, the models' SN and SP for ovarian cancer. Premenopausal cancer patients were considered without stage stratification due to the limited number of late stage cases.
